Clinical Information


In 2016, the Annals of Surgical Oncology published the results of the National Cancer Institute (NCI) Sponsored study ACOSOG (Alliance) Z1072 Phase II, single arm non-randomized study in the treatment of invasive breast disease. This study evaluated the rate of complete tumor ablation. The Visica® 2 Treatment System was the exclusive device used in this landmark study.

Study Design

  • Patients were treated with cryoablation
  • Eligible patients included those with univocal invasive ductal breast cancer ≤2.0 cm, with <25% intraductal component and tumor enhancement on MRI
  • A total of 19 centers contributed 99 patients, of which 86 patients (87 breast cancers) were evaluable for data analysis


  • 100% ablation in all tumors <1.0 cm in size, defined as no remaining invasive breast cancer (IBC) or ductal carcinoma in situ (DCIS) on pathological examination of the tumor
  • Cryoablation was effective in 92% of all targeted tumors
  • No cases were categorized as ineffective ablation within the cryoablation zone (all cancer cells within the treatment zone were killed)

To review the Z1072 abstract, please click here

Not finding what you're looking for?

We would love to help. Contact us today. Call us at 800-909-3060 or email clinical(at)sanarus.com.